Neurology & Brain Disorders Clinical Trials Update: Week 26, 2026

Published June 26, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Cannabidiol as add-on Therapy for Children With Refractory Epilepsy (CBD-uN1que), a High-quality Individualized Approach: a Series of N-of-1 Trials

This Phase 3 trial is exploring cannabidiol, a compound found in cannabis, as an additional treatment for children suffering from severe refractory epilepsy. These children have epilepsy that does not respond well to current medications. By alternating periods of cannabidiol and placebo, the study aims to see if cannabidiol can reduce seizures and improve quality of life. The trial is recruiting in the Netherlands and uses a personalized approach to determine treatment effectiveness for each child.

An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study

This Phase 3 study evaluated the long-term safety of AXS-05, an oral medication designed to treat agitation in patients with Alzheimer's disease. Agitation can be a distressing symptom for both patients and caregivers, and managing it well can improve daily living. The trial involved 139 participants across the United States and Puerto Rico and has now completed with results available, offering important information about this treatment option.

Imaging of Brain Amyloid Plaques in the Aging Population

This Phase 4 study uses a special brain scan called Pittsburgh Compound B PET to observe amyloid plaques, substances linked to Alzheimer's disease and related dementias. By tracking how these plaques change over time, researchers hope to improve diagnosis and monitoring of conditions like Alzheimer's, frontotemporal dementia, and vascular dementia. The study is enrolling adults in the United States who range from normal aging to varying levels of cognitive impairment.

Blood-based Biomarkers for Alzheimer's Disease at the Primary Care Level

This study is testing simple blood tests to help diagnose Alzheimer's disease early in primary care settings. Early and accurate diagnosis can lead to better treatment decisions and care planning. The trial, recruiting in Belgium with 240 participants, combines blood tests with clinical assessments to see if this approach can improve how Alzheimer's is detected and managed outside specialist clinics.

Robot-Assisted Meditation for Older Adults With Cognitive Concerns

This study is developing and testing a new meditation method using a handheld robot to help older adults who have memory or thinking concerns improve their sleep quality. Better sleep can reduce stress and support brain health. Although not yet recruiting, this trial aims to offer a medication-free way to practice mindfulness that may be more engaging and effective for older individuals.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.